Aug. 10 at 2:57 PM
$ORKA $MLTX that company lives off hype. Basically an overpriced phase 2 promise with an avg 30% success rate for phase 2 companies. If the mAb with extended life will have serious side effects which are common for mAbs the patient will have to endure a long period of suffering out of those symptoms. That will be no good. It's way to early for supporting such a price action, that is just speculation based on a promise, guaranteed if something goes wrong it will plumb down -90%. Remember: globally phase 2 companies have a 30% success rate.
